Proposal for Omaveloxolone (RTA 408)

Overview of Therapeutic Candidate:
Omaveloxolone, also known as RTA 408, is a semisynthetic triterpenoid originally developed from oleanolic acid derivatives and engineered to enhance intrinsic antioxidant defenses. This compound belongs to the class of synthetic triterpenoids that have been extensively studied for their anti‐inflammatory, anticancer, and antioxidative properties. Semisynthetic triterpenoids are produced by chemically modifying natural triterpenoid leads to improve potency, bioavailability, and pharmacokinetic properties. Omaveloxolone in particular was discovered based on its ability to bind to and neutralize Keap1, the protein that under normal conditions suppresses the nuclear factor erythroid 2-related factor 2 (Nrf2) by targeting it for ubiquitination and proteasomal degradation. As a member of this therapeutic class, omaveloxolone has been applied in several studies aimed at mitigating oxidative stress, and its chemical design leverages established structure–activity relationships seen in triterpenoids that modulate redox biology (Clay et al., 2019, pp. 1–3). Historically, similar compounds have been employed in preclinical oncology and inflammatory disease models, and more recently omaveloxolone has been repurposed for Friedreich’s Ataxia (FRDA) owing to its potent activation of Nrf2 signaling, with significant implications for diseases marked by mitochondrial dysfunction and oxidative stress (Scott et al., 2024, pp. 1–2).

Therapeutic History:
Omaveloxolone has been evaluated in multiple preclinical studies and clinical trials, particularly in the context of diseases where oxidative damage plays a central role. Preclinical data have shown that omaveloxolone upregulates Nrf2 target genes, thereby enhancing defense against reactive oxygen species (ROS) and improving mitochondrial oxidative capacity in models of FRDA (Lynch et al., 2019, pp. 1–2; Rodríguez et al., 2020, pp. 3–4). Early-phase clinical trials, including phase 1 studies in healthy volunteers, have detailed its pharmacokinetic and pharmacodynamic profiles, and phase 2 trials (e.g., ClinicalTrials.gov, 2015) demonstrated safety and dose-dependent transcriptional upregulation of antioxidant genes in FRDA patients (Lynch et al., 2021, pp. 1–2). Although not used historically in veterinary practice, omaveloxolone’s therapeutic class has been linked to antioxidant and anti-inflammatory interventions. Importantly, omaveloxolone has been investigated specifically for Friedreich’s Ataxia—a genetic neurodegenerative disease characterized by frataxin deficiency and mitochondrial dysfunction—and it is the first agent in its class to be approved in this indication for patients aged 16 years and older (Scott et al., 2024, pp. 5–6; Clay et al., 2019, pp. 3–4). Multiple studies, both preclinical and clinical, have also examined its efficacy in neuronal models, including patient-derived fibroblasts and induced pluripotent stem cell (iPSC) neurons, demonstrating improved mitochondrial respiration and reduced oxidative damage (Tiberi et al., 2023, pp. 7–8; Rodríguez et al., 2020, pp. 8–10).

Mechanism of Action:
The mechanism of action of omaveloxolone centers on its ability to activate the transcription factor Nrf2. Under basal conditions, Nrf2 is sequestered in the cytoplasm via its binding partner Keap1, which facilitates its ubiquitination and subsequent proteasomal degradation. Omaveloxolone works by binding directly to Keap1—specifically interacting with critical cysteine residues such as Cys151—thereby preventing Nrf2 sequestration (Tiberi et al., 2023, pp. 15–16; La Rosa et al., 2020b, pp. 10–12). This disruption releases Nrf2 from Keap1, allowing it to translocate to the nucleus where it heterodimerizes with small Maf proteins, binding to antioxidant response elements (ARE) in the promoter regions of target genes. Activation of Nrf2 results in the transcriptional upregulation of a battery of genes encoding antioxidant enzymes, including but not limited to NAD(P)H quinone dehydrogenase 1 (NQO1), heme oxygenase-1 (HO-1), superoxide dismutases (SODs), and enzymes involved in glutathione synthesis (Strawser et al., 2017, pp. 10–13; La Rosa et al., 2020b, pp. 10–12). This cascade of antioxidant gene expression confers cellular protection against ROS and has been implicated in the restoration of mitochondrial respiratory capacity by indirectly reducing oxidative damage to iron-sulfur (Fe-S) clusters. In the context of Friedreich’s Ataxia, where frataxin deficiency leads to impaired Fe-S cluster biogenesis and resultant mitochondrial dysfunction, omaveloxolone’s mechanism offers a twofold benefit: it attenuates oxidative stress through enhanced antioxidant defenses and may promote an environment conducive to improved mitochondrial bioenergetics and possibly even a modest increase in frataxin expression via indirect regulatory effects on the FXN gene (Tai et al., 2018, pp. 3–4; Lynch et al., 2021, pp. 13–14). Preclinical studies in FRDA patient-derived iPSC neurons have shown that treatment with omaveloxolone increases oxygen consumption rate (OCR) and mitochondrial function, which supports its proposed mechanism of reversing mitochondrial impairment (Tiberi et al., 2023, pp. 16–18).

Expected Effect:
Based on the hypothesis and preclinical data, omaveloxolone is expected to activate the Nrf2 pathway in FRDA patient-derived fibroblasts and neurons, leading to the upregulation of antioxidant genes that combat excessive ROS production and oxidative damage. In the proposed assays, one would expect to observe increased expression of Nrf2 target genes such as HO-1, NQO1, and genes involved in glutathione synthesis, which collectively contribute to improved cellular redox homeostasis (Rodríguez et al., 2020, pp. 4–5). This upregulation should, in turn, protect and restore mitochondrial function by minimizing oxidative damage to mitochondrial DNA and Fe-S cluster-containing enzymes, thereby improving the respiratory capacity of affected cells (Tiberi et al., 2023, pp. 7–8; Scott et al., 2024, pp. 3–5). Moreover, although direct upregulation of frataxin by omaveloxolone has not been consistently demonstrated, the enhanced antioxidant response can indirectly alleviate the oxidative stress that exacerbates frataxin deficiency, potentially normalizing some aspects of Fe-S cluster assembly and mitochondrial bioenergetics (Clay et al., 2019, pp. 13–14; Lynch et al., 2019, pp. 11–12). In assays using FRDA fibroblasts and neurons, one could measure parameters such as decreased ROS levels, improved mitochondrial membrane potential, increased ATP production, and better oxygen consumption rates (Tiberi et al., 2023, pp. 20–22; Rodríguez et al., 2020, pp. 8–10). The presence and function of Nrf2 in these cell types are well documented, and previous studies have confirmed that the Nrf2 pathway is downregulated in FRDA, supporting the assay’s rationale (Rodríguez et al., 2020, pp. 22–24; La Rosa et al., 2020a, pp. 3–5).

Overall Evaluation:
Omaveloxolone appears to be a highly promising therapeutic candidate for Friedreich’s Ataxia based on both its mechanism of action and the preclinical/clinical evidence available. Strengths of this candidate include its specific mechanism of action—targeting the Nrf2 pathway through direct Keap1 binding—which addresses a core pathological feature of FRDA by restoring the antioxidant capacity and improving mitochondrial function (Tiberi et al., 2023, pp. 15–16; Scott et al., 2024, pp. 10–11). The compound’s extensive preclinical characterization in FRDA models, including evidence from patient-derived fibroblast studies and iPSC-derived neurons, provides reassurance about its potential to reverse oxidative damage and improve cellular respiration (Lynch et al., 2019, pp. 1–2; Tai et al., 2018, pp. 2–3). Additionally, robust clinical data from phase 2 studies indicate that omaveloxolone is safe and well tolerated in FRDA patients, with clear dose-dependent transcriptional upregulation of Nrf2-driven genes, which supports its translational potential (ClinicalTrials.gov, 2015; Lynch et al., 2021, pp. 1–2).

However, there are some limitations to consider. While the indirect increase in frataxin expression is appealing, the current literature suggests that omaveloxolone does not directly modulate FXN expression but instead works by mitigating downstream oxidative stress consequences, which may limit the extent of clinical benefit if frataxin deficiency remains severe (Clay et al., 2019, pp. 3–4; Rodríguez et al., 2020, pp. 3–4). Moreover, the heterogeneity in patient responses, as observed in clinical trials, and potential issues relating to achieving optimal dosing in specific subpopulations (such as pediatric versus adult patients) remain challenges that require further investigation (ClinicalTrials.gov, 2024a; Scott et al., 2024, pp. 3–5). There is also the need to closely monitor for off-target effects and toxicity, particularly in long-term use, given that triterpenoids have been associated with relatively complex safety profiles in some contexts (Lynch et al., 2019, pp. 11–12; ClinicalTrials.gov, 2024b). Nonetheless, the availability of detailed clinical-stage PK/ADME data and established safety profiles through multiple phase 1 and 2 studies positions omaveloxolone for rapid development and potential regulatory approval (ClinicalTrials.gov, 2018; ClinicalTrials.gov, 2024c).

In summary, omaveloxolone’s ability to activate Nrf2 and thereby upregulate antioxidant defenses addresses key pathological drivers in Friedreich’s Ataxia, namely oxidative stress and mitochondrial dysfunction due to frataxin deficiency. Its extensive preclinical validation in patient-derived models combined with encouraging clinical trial data support its further development as a disease-modifying therapy for FRDA (Strawser et al., 2017, pp. 30–33; Subramony & Lynch, 2024, pp. 1–2). While additional studies are necessary to optimize dosing and provide long-term efficacy and safety insights, the strengths of omaveloxolone—in terms of target specificity, mechanistic rationale, and robust early-phase data—strongly endorse its consideration as a therapeutic candidate for Friedreich’s Ataxia (Tiberi et al., 2023, pp. 1–2; Clay et al., 2019, pp. 1–3).

References:
ClinicalTrials.gov. (n.d.). Omaveloxolone OR RTA 408 AND Friedreich’s ataxia. Retrieved from https://clinicaltrials.gov
ClinicalTrials.gov. (2015). RTA 408 capsules in patients with Friedreich’s ataxia (MOXIe) [Clinical trial registration NCT02255435]. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02255435
ClinicalTrials.gov. (2018). A pharmacokinetic study of omaveloxolone in healthy volunteers [Clinical trial registration NCT03664453]. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03664453
ClinicalTrials.gov. (2024a). A study of omaveloxolone in children with Friedreich’s ataxia [Clinical trial registration NCT06054893]. Retrieved from https://clinicaltrials.gov/ct2/show/NCT06054893
ClinicalTrials.gov. (2024b). A study to learn more about the long-term safety of BIIB141 (Omaveloxolone) in participants with Friedreich’s ataxia who are prescribed it for the first time [Clinical trial registration NCT06623890]. Retrieved from https://clinicaltrials.gov/ct2/show/NCT06623890
ClinicalTrials.gov. (2024c). SKYCLARYS® (Omaveloxolone) Pregnancy and Lactation Surveillance Program [Clinical trial registration NCT06628687]. Retrieved from https://clinicaltrials.gov/ct2/show/NCT06628687
Clay, A., Hearle, P., Schadt, K., & Lynch, D. R. (2019). New developments in pharmacotherapy for Friedreich ataxia. Expert Opinion on Pharmacotherapy, 20, 1855–1867. https://doi.org/10.1080/14656566.2019.1639671
La Rosa, P., Bertini, E. S., & Piemonte, F. (2020b). The Nrf2 signaling network defines clinical biomarkers and therapeutic opportunity in Friedreich’s ataxia. International Journal of Molecular Sciences, 21, 916. https://doi.org/10.3390/ijms21030916
La Rosa, P., Petrillo, S., Bertini, E. S., & Piemonte, F. (2020a). Oxidative stress in DNA repeat expansion disorders: A focus on Nrf2 signaling involvement. Biomolecules, 10, 702. https://doi.org/10.3390/biom10050702
Lynch, D. R., Farmer, J., Hauser, L., Blair, I. A., Wang, Q. Q., Mesaros, C., Snyder, N., Boesch, S., Chin, M., Delatycki, M. B., Giunti, P., Goldsberry, A., Hoyle, C., McBride, M. G., Nachbauer, W., O’Grady, M., Perlman, S., Subramony, S. H., Wilmot, G. R., Zesiewicz, T., & Meyer, C. (2019). Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Annals of Clinical and Translational Neurology, 6, 15–26. https://doi.org/10.1002/acn3.660
Lynch, D. R., Chin, M. P., Mariotti, C., Mathews, K. D., Delatycki, M. B., Subramony, S. H., Corti, M., Hoyle, J. C., Boesch, S., Nachbauer, W., Giunti, P., Wilmot, G., Zesiewicz, T., Perlman, M. S., Goldsberry, A., O’Grady, M., & Meyer, C. J. (2021). Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Annals of Neurology, 89, 212–225. https://doi.org/10.1002/ana.25934
Rodríguez, L. R., Lapeña, T., Calap-Quintana, P., Moltó, M. D., Gonzalez-Cabo, P., & Navarro Langa, J. A. (2020). Antioxidant therapies and oxidative stress in Friedreich’s ataxia: The right path or just a diversion? Antioxidants, 9, 664. https://doi.org/10.3390/antiox9080664
Scott, V., Delatycki, M. B., Tai, G., & Corben, L. A. (2024). New and emerging drug and gene therapies for Friedreich ataxia. CNS Drugs, 38, 791–805. https://doi.org/10.1007/s40263-024-01113-z
Strawser, C., Schadt, K., Hauser, L., McCormick, A., Wells, M., Larkindale, J., Lin, H., & Lynch, D. R. (2017). Pharmacological therapeutics in Friedreich ataxia: The present state. Expert Review of Neurotherapeutics, 17, 895–907. https://doi.org/10.1080/14737175.2017.1356721
Subramony, S. H., & Lynch, D. L. (2024). A milestone in the treatment of ataxias: Approval of omaveloxolone for Friedreich ataxia. The Cerebellum, 23, 775–777. https://doi.org/10.1007/s12311-023-01568-8
Tai, G., Corben, L. A., Yiu, E. M., Milne, S. C., & Delatycki, M. B. (2018). Progress in the treatment of Friedreich ataxia. Neurologia i Neurochirurgia Polska, 52, 129–139. https://doi.org/10.1016/j.pjnns.2018.02.003
Tiberi, J., Segatto, M., Fiorenza, M. T., & La Rosa, P. (2023). Apparent opportunities and hidden pitfalls: The conflicting results of restoring Nrf2-regulated redox metabolism in Friedreich’s ataxia pre-clinical models and clinical trials. Biomedicines, 11, 1293. https://doi.org/10.3390/biomedicines11051293
